O-12 NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal
Van K. Morris(The University of Texas MD Anderson Cancer Center), Cathy Eng(Vanderbilt University), Howard S. Höchster(Rutgers, The State University of New Jersey), Al B. Benson(Northwestern University), Olivia Aranha(Washington University in St. Louis), Kristen K. Ciombor(Vanderbilt University Medical Center), Benjamin A. Weinberg(Georgetown University), Blasé N. Polite(Sidney Kimmel Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Syma Iqbal(USC Norris Comprehensive Cancer Center), Anthony F. Shields(Wayne State University), Syed Mohammad Ali Kazmi(The University of Texas Southwestern Medical Center), Sarbajit Mukherjee(Roswell Park Comprehensive Cancer Center), John L. Hays(The Ohio State University), John C. Krauss(University of Michigan), Christopher H. Lieu(University of Colorado Denver)
Cited by 9
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k